Indaptus Amends S-1, Reveals Recent Capital Raises Totaling Millions

TL;DR

**INDP is a cash-hungry biotech, constantly diluting shareholders to stay afloat; proceed with extreme caution.**

AI Summary

Indaptus Therapeutics, Inc. (INDP) filed an S-1/A on September 3, 2025, primarily to include an Engagement Agreement with H.C. Wainwright & Co., LLC. The company has been actively raising capital through various unregistered offerings. In June 2025, INDP completed a private placement, selling convertible notes totaling approximately $5.7 million, which converted into 501,566 common shares at $8.302 per share, along with pre-funded warrants for 190,795 shares and warrants for 1,384,722 shares. Additionally, placement agent warrants for 83,083 shares were issued. Earlier in February 2025, INDP entered a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. for up to $20.0 million, having already issued 89,902 shares for approximately $1.85 million. A January 2025 private placement raised capital by selling 75,335 common shares and warrants, with an exercise price of $26.32 per share. The company also conducted registered direct offerings in November 2024 and August 2024, generating gross proceeds of approximately $2.13 million and $3.0 million, respectively, before expenses. Total estimated expenses for the current registration are $100,000, including $70,000 for legal fees and $20,000 for accounting fees.

Why It Matters

This S-1/A filing highlights Indaptus Therapeutics' ongoing reliance on dilutive financing to fund operations, a critical factor for investors assessing future share value. The series of private placements and registered direct offerings, including the $5.7 million convertible note sale in June 2025 and the $20.0 million SEPA with YA II PN, LTD., indicates a continuous need for capital in this pre-revenue biotech. For employees, sustained funding means continued operations, while customers (future patients) depend on this capital for drug development. Competitively, frequent capital raises suggest the company is burning cash to advance its pipeline, a common but risky strategy in the biotech sector.

Risk Assessment

Risk Level: high — The company's frequent and significant capital raises, including a $5.7 million convertible note offering in June 2025 and a $20.0 million standby equity purchase agreement, indicate a high burn rate and continuous need for external funding. The issuance of numerous warrants (e.g., 1,384,722 shares in June 2025, 75,335 shares in January 2025) suggests substantial potential future dilution for existing shareholders, posing a significant risk to share price stability and investor returns.

Analyst Insight

Investors should carefully evaluate INDP's cash position and burn rate, as the company's consistent reliance on dilutive financing suggests ongoing capital needs. Consider the impact of potential future warrant exercises and standby equity purchases on share count before making any investment decisions.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $5.7 million — Aggregate principal amount of convertible notes (Sold in June 2025 private placement)
• 501,566 — Shares of common stock (Converted from convertible notes at $8.302 per share in June 2025)
• 1,384,722 — Warrants to purchase common stock (Issued in June 2025 private placement)
• $20.0 million — Maximum amount under Standby Equity Purchase Agreement (SEPA) (Agreement with YA II PN, LTD. from February 2025)
• $1.85 million — Aggregate gross proceeds from Advance Shares (Received from YA II PN, LTD. as of filing date)
• 75,335 — Unregistered shares of common stock (Sold in January 2025 private placement)
• $2.13 million — Gross proceeds from November 2024 registered direct offering (Before deducting placement agent and other offering expenses)
• $3.0 million — Gross proceeds from August 2024 registered direct offering (Before deducting placement agent and other offering expenses)
• $100,000 — Total estimated expenses for registration (Includes legal and accounting fees)
• $70,000 — Legal Fees and Expenses (Estimated cost for the current registration)

Key Players & Entities

• Indaptus Therapeutics, Inc. (company) — Registrant in S-1/A filing
• Jeffrey A. Meckler (person) — Chief Executive Officer of Indaptus Therapeutics, Inc.
• YA II PN, LTD. (company) — Investor in Standby Equity Purchase Agreement (SEPA) with Indaptus
• H.C. Wainwright & Co., LLC (company) — Placement agent and party to Engagement Agreement
• Greenberg Traurig LLP (company) — Legal counsel for Indaptus Therapeutics, Inc.
• Haynes and Boone, LLP (company) — Legal counsel for Indaptus Therapeutics, Inc.
• Paulson Investment Company, LLC (company) — Placement agent for January 2025 financing
• Lincoln Park Capital Fund, LLC (company) — Former investor in a terminated purchase agreement
• Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing
• Delaware General Corporation Law (regulator) — Governing law for corporate indemnification

FAQ

Risk Factors

• Reliance on Future Capital Raises [high — financial]: The company has a history of relying on various unregistered offerings and registered direct offerings to fund operations, including a $5.7 million convertible note placement in June 2025 and a $20.0 million SEPA with YA II PN, LTD. in February 2025. Future funding is contingent on the success of these capital raises and the current registration, posing a significant financial risk if market conditions or investor sentiment shift.
• Unregistered Offerings and Registration Compliance [medium — regulatory]: Indaptus has conducted multiple unregistered offerings, raising capital through convertible notes and private placements. The current S-1/A filing aims to register securities from these past offerings and potentially future ones. Non-compliance with securities laws regarding unregistered offerings could lead to regulatory scrutiny and penalties.
• Dependence on H.C. Wainwright Engagement [medium — operational]: The S-1/A filing is primarily to include an Engagement Agreement with H.C. Wainwright & Co., LLC. This highlights a reliance on specific financial intermediaries for capital raising and market support, which could be a vulnerability if the relationship sours or the firm's capabilities are insufficient.
• Dilution from Warrants and Convertible Notes [high — financial]: The company has issued a substantial number of warrants (1,384,722 in June 2025) and convertible notes that convert into shares. These instruments, along with pre-funded warrants and placement agent warrants, create significant potential dilution for existing shareholders, impacting the value of their holdings.

Industry Context

Indaptus Therapeutics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often rely on significant funding rounds to finance research and development, clinical trials, and regulatory approvals. The success of biotech firms is heavily dependent on scientific innovation, intellectual property protection, and the ability to navigate complex regulatory pathways.

Regulatory Implications

The company's reliance on various unregistered offerings and the current S-1/A filing highlight potential regulatory risks. Ensuring compliance with SEC regulations regarding the sale of securities, particularly exemptions for private placements, is critical. Failure to adhere to these rules can result in significant penalties and legal challenges.

What Investors Should Do

1. Monitor future capital raises closely, as the company's funding strategy appears heavily reliant on equity and debt issuances, which can lead to significant dilution.
2. Evaluate the terms and potential dilution associated with outstanding warrants and convertible notes, particularly those issued in recent private placements and the SEPA.
3. Assess the company's progress in its clinical development pipeline, as this will be the primary driver of long-term value, given the current funding-centric narrative.
4. Understand the implications of the H.C. Wainwright & Co., LLC engagement, as it signals a reliance on this firm for future market activities and capital access.

Key Dates

• 2025-09-03: Filing of S-1/A — Indicates the company's intent to register securities and potentially raise further capital, including an engagement with H.C. Wainwright & Co., LLC.
• 2025-06-01: Private Placement of Convertible Notes — Raised approximately $5.7 million, which converted into common shares and warrants, demonstrating ongoing capital-raising activities.
• 2025-02-01: Standby Equity Purchase Agreement (SEPA) — Agreement with YA II PN, LTD. for up to $20.0 million, with $1.85 million already drawn, showing a flexible but potentially dilutive funding mechanism.
• 2025-01-01: Private Placement — Raised capital by selling common shares and warrants, continuing the pattern of equity financings.
• 2024-11-01: Registered Direct Offering — Generated approximately $2.13 million in gross proceeds, indicating the use of registered offerings to access capital markets.
• 2024-08-01: Registered Direct Offering — Generated approximately $3.0 million in gross proceeds, showing a consistent strategy of public equity raises.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC. It's used to update or correct information in the original S-1 filing before an IPO or other public offering. (This filing indicates Indaptus is seeking to register securities, likely to facilitate ongoing or future capital raises.)

Convertible Notes

Debt instruments that can be converted into a predetermined amount of equity (common stock) at the option of the noteholder. (Indaptus issued $5.7 million in convertible notes in June 2025, which converted into shares, impacting share count and potentially diluting existing shareholders.)

Pre-funded Warrants

Warrants that allow the holder to purchase a share of common stock for a nominal exercise price (e.g., $0.01), effectively representing immediate ownership of the share upon exercise. (Issued alongside convertible notes in June 2025, these also contribute to the potential increase in outstanding shares.)

Standby Equity Purchase Agreement (SEPA)

An agreement where an investor commits to purchase a certain amount of a company's stock over a period, typically at the company's discretion, often at a discount to market price. (Indaptus has a $20.0 million SEPA with YA II PN, LTD., providing a flexible but potentially dilutive source of capital.)

Registered Direct Offering

A type of public offering where a company sells newly issued shares directly to investors, with the shares being registered with the SEC. (Indaptus has utilized these offerings in August and November 2024 to raise capital, generating $3.0 million and $2.13 million respectively.)

Placement Agent Warrants

Warrants issued to the agents or brokers who help facilitate a securities offering, as compensation for their services. (Issued in the June 2025 private placement, these represent additional potential dilution.)

Year-Over-Year Comparison

This S-1/A filing does not provide comparative financial data from a prior year's filing. However, it details a series of capital-raising activities throughout 2024 and 2025, including registered direct offerings, private placements of convertible notes, and a standby equity purchase agreement. These activities suggest a continuous need for funding to support operations and development, rather than a comparison of growth in revenue or profitability from a previous period.

Key Financial Figures

• $5.7 m — egate principal amount of approximately $5.7 million, which automatically converted in
• $8.302 — r common stock at a conversion price of $8.302 per share and pre-funded warrants to pu
• $20.0 million — h we have the right to sell to YA up to $20.0 million in shares of our common stock subject t
• $1.85 million — gregate gross proceeds of approximately $1.85 million. In the SEPA, YA represented to Indaptu
• $26.32 — ely exercisable at an exercise price of $26.32 per share and expire five years from th
• $32.90 — at an exercise price per share equal to $32.90. The placement agent warrants are exerc
• $29.40 — ely exercisable at an exercise price of $29.40 per share and expire five years from th
• $32 — are of common stock and one warrant was $32.90, resulting in gross proceeds of appr
• $2.13 m — ting in gross proceeds of approximately $2.13 million, before deducting placement agent
• $0.345 million — expenses in the amount of approximately $0.345 million. In connection with the November 2024 f
• $36.75 — at an exercise price per share equal to $36.75. The placement agent warrants are exerc
• $47.60 — ely exercisable at an exercise price of $47.60 per share and expire five years from th
• $51 — are of common stock and one warrant was $51.10, resulting in gross proceeds of appr
• $3.0 m — ting in gross proceeds of approximately $3.0 million, before deducting placement agent
• $0.5 million — expenses in the amount of approximately $0.5 million. II-2 On December 22, 2022, Indaptu

Filing Documents

• forms-1a.htm (S-1/A) — 153KB
• ex10-31.htm (EX-10.31) — 74KB
• ex10-31_001.jpg (GRAPHIC) — 11KB
• 0001641172-25-026333.txt ( ) — 243KB

financial statements and related notes thereto

financial statements and related notes thereto. Exhibit Index Exhibit No. Exhibit Description 3.1 Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc., dated as of July 23, 2021 (incorporated herein by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 23, 2021) 3.2 Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of January 22, 2024 (incorporated herein by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2024) 3.3 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc. dated August 3, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2021) 4.1* Form of Common Warrant to be sold in the offering 4.2* Form of Pre-Funded Warrant to be sold in the offering 4.3* Form of Placement Agent Warrant 4.4 Description of Securities Registered under Section 12 (incorporated herein by reference to Exhibit 4.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2021) 4.5 Form of Ordinary Share Purchase Warrant of Intec Parent, Inc. (incorporated herein by reference to Exhibit 10.2 to Intec Israel’s Current Report on Form 8-K filed with the SEC on May 6, 2020) 4.6 Form of Series A Common Stock Purchase Warrant of Intec Parent, Inc. (incorporated herein by reference to Exhibit 10.3 to Indaptus’ Current Report on Form 8-K filed with the SEC on July 29, 2021) II-3 5.1* Opinion of Greenberg Traurig LLP 10.1+ Indaptus Therapeutics, Inc. Amended and Restated 2021 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on June 7, 2024) 10.2+ Form of Option Award Agreement (incorporated herein by reference to Exhibit

View Full Filing

View this S-1/A filing on SEC EDGAR